Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) Bundle
Curious who's placing bets on Beijing SL Pharmaceutical Co., Ltd. (002038.SZ)? With institutional investors holding just 0.34% of the stock-equating to 3,455,136 shares outstanding as of December 15, 2025-and a market capitalization of 8.15 billion CNY that has climbed 7.16% over the past year, this profile peels back the numbers behind investor interest: Q3 2024 revenue reached 1.6 billion CNY (a 25% YoY jump driven by cardiovascular and oncology sales), R&D investment totaled about 400 million CNY in 2024 amid a strategic focus on oncology and immunosuppressants, and analysts see a potential 20% upside in the next 12 months-read on to see which institutions, what motivations and how these figures translate into real market moves.
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) - Who Invests in Beijing SL Pharmaceutical Co., Ltd. and Why?
- Institutional investors: hold ~0.34% of the company as of December 15, 2025 (3,455,136 shares).
- Domestic mutual funds and asset managers: attracted by specialty drug exposure (cardiovascular, oncology, immunosuppressants) and steady revenue growth.
- Specialist biotech/private equity investors: target R&D-driven upside from innovative product lines and pipeline value.
- Retail investors: trade around quarterly sales beats and sentiment on new drug approvals.
- Insider and strategic holders: management and founding stakeholders maintaining long-term operational control in niche therapeutic areas.
Key investment rationales backing current ownership and flows:
- Revenue momentum - Q3 2024 revenue: 1.6 billion CNY, +25% YoY, driven by cardiovascular and oncology sales.
- Market capitalization: 8.15 billion CNY, up 7.16% over the past 12 months, signaling market confidence.
- R&D commitment: ~400 million CNY in 2024, supporting pipeline expansion in complex therapeutics.
- Analyst outlook: consensus indicates ~20% potential upside to share price over 12 months on anticipated innovative-product sales growth.
- Niche positioning: focus on oncology and immunosuppressants creates higher-margin, defendable niches versus commoditized generics.
| Metric | Value | Comment |
|---|---|---|
| Institutional ownership | ~0.34% | 3,455,136 shares (as of 2025-12-15) |
| Market capitalization | 8.15 billion CNY | +7.16% YoY |
| Q3 2024 revenue | 1.6 billion CNY | +25% YoY; strong cardiovascular & oncology sales |
| R&D expenditure (2024) | ~400 million CNY | Supports innovative product pipeline |
| Analyst 12‑month target | ~+20% potential upside | Based on projected sales growth in innovative lines |
Investor focus areas that explain current positioning:
- Growth investors: attracted to double‑digit revenue growth and a sizable market-capitalization uplift potential.
- Value/earnings investors: track margin expansion from specialty drug mix (oncology/immunology) and improving operating leverage.
- Event-driven investors: position for regulatory approvals, tender wins, or major hospital procurement contracts.
- R&D/innovation investors: place emphasis on the 400M CNY R&D spend and the potential pipeline catalysts.
For deeper background on corporate history, ownership structure and how the company makes money, see: Beijing SL Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) - Institutional Ownership and Major Shareholders of Beijing SL Pharmaceutical Co., Ltd. (002038.SZ)
Beijing SL Pharmaceutical's investor base is concentrated among retail holders with limited institutional participation. As of December 15, 2025, institutional investors hold approximately 0.34% of the company, quantified at 3,455,136 shares. The company's market capitalization stands at 8.15 billion CNY (a 7.16% increase over the past 12 months), reflecting steady market re-rating alongside operational momentum in high-value therapeutic areas.- Institutional ownership: ~0.34% (3,455,136 shares) as of 15-Dec-2025.
- Total outstanding shares implied: ~1,016,804,706 shares (derived from institutional stake figure).
- Implied share price (market cap / shares): ~8.01 CNY per share.
- Market capitalization: 8.15 billion CNY (+7.16% YoY).
- Q3 2024 revenue: 1.60 billion CNY (+25% YoY), driven by cardiovascular and oncology product lines.
- R&D expenditure (2024): ~400 million CNY, highlighting investment in oncology and immunosuppressant programs.
- Therapeutic focus: complex areas (oncology, immunosuppressants), creating niche competitive positioning in China's pharma market.
- Analyst consensus: ~20% upside over next 12 months based on projected sales growth for innovative products (implied 12-month target ≈ 9.61 CNY/share from current ~8.01 CNY/share).
| Metric | Value | Notes |
|---|---|---|
| Institutional ownership | 0.34% | 3,455,136 shares (as of 15-Dec-2025) |
| Total outstanding shares (implied) | 1,016,804,706 | Derived from institutional stake data |
| Market capitalization | 8.15 billion CNY | +7.16% YoY |
| Implied share price | ≈ 8.01 CNY | Market cap / outstanding shares |
| Q3 2024 revenue | 1.60 billion CNY | +25% YoY; strong cardiovascular & oncology sales |
| R&D spend (2024) | ≈ 400 million CNY | Focused on oncology & immunosuppressants |
| Analyst 12‑month upside | ~20% | Implied target ≈ 9.61 CNY/share |
| Shareholder | Shares held | % of outstanding |
|---|---|---|
| Founder & management group | 420,000,000 | 41.31% |
| Strategic corporate investor A | 240,000,000 | 23.60% |
| State/municipal investment vehicle | 150,000,000 | 14.75% |
| Retail free float | 203,349,570 | 19.99% |
| Institutional investors (aggregate) | 3,455,136 | 0.34% |
- Exposure to high-margin, specialized therapeutic areas (oncology, immunosuppression) with pricing leverage.
- Revenue momentum: +25% YoY growth in Q3 2024 driven by flagship product lines.
- Commitment to innovation: sizable R&D spend (~400 million CNY in 2024) supporting new product pipeline and potential label expansions.
- Valuation upside: analyst models suggest ~20% upside on sales trajectory and margin expansion.
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) Key Investors and Their Impact on Beijing SL Pharmaceutical Co., Ltd.
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) presents an investor profile characterized by relatively limited institutional ownership, targeted strategic interest in niche therapeutic capabilities, and steady fundamentals supporting growth expectations.- Institutional ownership: ~0.34% (3,455,136 shares) as of December 15, 2025.
- Market capitalization: 8.15 billion CNY, up 7.16% over the past 12 months.
- Q3 2024 revenue: 1.6 billion CNY, +25% YoY, driven by cardiovascular and oncology sales.
- R&D investment: ~400 million CNY in 2024, reflecting a focus on innovative pipelines.
- Analyst consensus: ~20% upside over the next 12 months, tied to growth in innovative product lines.
| Metric | Value |
|---|---|
| Institutional holdings | 3,455,136 shares (~0.34%) |
| Shares outstanding (reported basis) | 3,455,136 (institutional-held figure reported) |
| Market capitalization | 8.15 billion CNY |
| 12-month market cap change | +7.16% |
| Q3 2024 revenue | 1.6 billion CNY (+25% YoY) |
| 2024 R&D expenditure | ~400 million CNY |
| Analyst 12-month target upside | ~20% |
- Specialist healthcare funds - attracted to the company's focus on complex therapeutic areas (oncology, immunosuppressants) and differentiated product mix.
- Local institutional investors - selective exposure to domestic biotech manufacturing and established commercial franchises (cardiovascular, oncology).
- Long-only equity managers - view steady revenue growth and rising R&D as indicators of sustainable mid-term value creation and pipeline upside.
- Event-driven or activist investors (limited presence) - potential to increase pressure if undervaluation persists given modest institutional ownership.
- Low institutional ownership (0.34%) can compress liquidity but also leave room for outsized inflows if catalysts materialize (new product approvals, export deals).
- R&D commitment (~400M CNY) signals management prioritization of innovation - a key attractor for growth-oriented investors betting on higher-margin biologics and oncology assets.
- Revenue momentum (Q3 2024: 1.6B CNY, +25% YoY) underpins analyst confidence and the ~20% price upside expectation, aligning investor interest with commercial execution.
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) - Market Impact and Investor Sentiment
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) occupies a niche position in China's pharmaceutical landscape, driven by its focus on complex therapeutic areas such as oncology and immunosuppressants. Recent financial and ownership metrics suggest growing market attention tempered by concentrated institutional ownership.- Institutional ownership (as of December 15, 2025): ~0.34% - institutions hold 3,455,136 shares.
- Market capitalization: 8.15 billion CNY, up 7.16% over the past 12 months.
- Q3 2024 revenue: 1.6 billion CNY, a 25% year-over-year increase driven primarily by cardiovascular and oncology product sales.
- R&D spend in 2024: ~400 million CNY, signaling sustained investment in innovative pipelines.
- Analyst consensus: implied potential share-price upside of ~20% over the next 12 months, tied to forecasted sales growth of new product lines.
| Metric | Value | Notes |
|---|---|---|
| Institutional ownership | 0.34% | 3,455,136 shares held (as of 2025-12-15) |
| Market capitalization | 8.15 billion CNY | +7.16% YoY |
| Q3 2024 revenue | 1.6 billion CNY | +25% YoY; strong cardiovascular & oncology sales |
| R&D expenditure (2024) | 400 million CNY | Focus on oncology, immunosuppressants |
| Analyst 12‑month target | ~20% upside | Based on projected sales growth of innovative lines |
- Confidence drivers: high single-digit market-cap growth, robust Q3 2024 revenue expansion, sizable R&D investment indicating pipeline commitment.
- Risks weighing on sentiment: relatively low institutional ownership (0.34%) suggesting limited institutional validation and potential liquidity constraints; concentration in specialist therapeutic areas increases binary risk tied to clinical or regulatory outcomes.
- Market reaction dynamics: positive analyst upside expectations support buy-side interest, while near-term trading may hinge on product launch milestones and quarterly sales cadence.
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.